{"gene":"GNA11","run_date":"2026-04-28T18:06:53","timeline":{"discoveries":[{"year":2010,"finding":"Somatic activating mutations in GNA11 (Q209L/P at codon 209, R183 at exon 4) constitutively activate the MAPK pathway and induce spontaneously metastasizing tumors in a mouse model, establishing GNA11 as an oncogenic driver in uveal melanoma.","method":"Tumor sequencing, mouse model with GNA11-mutant melanocytes, MAPK pathway assays","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 — in vivo mouse model + pathway activation assay, highly cited foundational study","pmids":["21083380"],"is_preprint":false},{"year":2013,"finding":"GNAQ or GNA11 mutation consistently activates both PKC and MAPK pathways in uveal melanoma; PKC acts upstream of MAPK activation, as PKC inhibition suppresses ERK signaling selectively in GNAQ/GNA11-mutant cells.","method":"PKC inhibitor treatment (AEB071, AHT956), MEK inhibitor treatment, signaling assays in mutant vs. wild-type cell lines, xenograft tumor models","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple inhibitors, in vitro and in vivo, epistasis demonstrated by pathway assays","pmids":["24141786"],"is_preprint":false},{"year":2014,"finding":"Germline gain-of-function GNA11 mutation (R60L) causes autosomal dominant hypoparathyroidism by increasing intracellular calcium accumulation in response to extracellular calcium with decreased EC50, demonstrating GNA11 couples the calcium-sensing receptor (CaSR) to intracellular calcium signaling in parathyroid cells.","method":"Whole-exome sequencing, functional expression of mutant Gα11 R60L in HEK293-CaR cells, intracellular calcium concentration measurement","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1 — in vitro functional reconstitution with mutant protein in CaSR-expressing cells, quantitative EC50 measurement","pmids":["24823460"],"is_preprint":false},{"year":2016,"finding":"Loss-of-function GNA11 mutation (Thr54Met), located at the interface between the Gα11 helical and GTPase domains, impairs GDP binding and interdomain interactions, resulting in reduced CaSR-mediated intracellular calcium signaling (rightward shift of concentration-response curve), causing familial hypocalciuric hypercalcemia type 2 (FHH2).","method":"3D homology modeling of Gα11, functional expression in HEK293-CaSR cells, flow cytometry-based intracellular calcium measurement","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1 — structural modeling + in vitro functional assay with quantitative signaling measurement","pmids":["26729423"],"is_preprint":false},{"year":2016,"finding":"In vitro expression of mutant GNA11(R183C) activates downstream p38 MAPK signaling pathway, while GNA11(Q209L) activates p38, JNK, and ERK pathways in human cell lines.","method":"Transient expression of mutant GNA11 in human cell lines, pathway signaling assays; transgenic mosaic zebrafish model","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro cell expression plus in vivo zebrafish model, single lab","pmids":["26778290"],"is_preprint":false},{"year":2017,"finding":"GNA11 loss-of-function mutation Phe220Ser disrupts a hydrophobic cleft region critical for activation of phospholipase C (PLC); mutant Gα11 impairs CaSR-mediated intracellular calcium and ERK MAPK signaling, consistent with diminished PLC activation. Engineered mutagenesis of the hydrophobic cleft confirmed its role in PLC signaling.","method":"Homology modeling, transient transfection of mutant Gα11 in HEK293-CaSR cells, intracellular calcium and ERK signaling assays, site-directed mutagenesis of hydrophobic cleft residues, cinacalcet rescue in vitro and in vivo","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1 — structure-guided mutagenesis + in vitro functional reconstitution + in vivo validation","pmids":["28833550"],"is_preprint":false},{"year":2018,"finding":"GNA11(Q209L)-driven uveal melanoma requires RasGRP3 for GNAQ/GNA11-driven Ras activation and tumorigenesis; RasGRP3 is a critical signaling node downstream of mutant GNA11/GNAQ linking G protein activation to Ras/MAPK signaling.","method":"GNA11(Q209L) transgenic mouse model, integrative transcriptome analysis of human and murine melanomas, siRNA knockdown in human UM cell lines, in vivo tumor models","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — genetic mouse model + human cell line knockdown + transcriptome analysis, replicated in murine and human systems","pmids":["29490280"],"is_preprint":false},{"year":2018,"finding":"GNA11 knockdown in fetoplacental endothelial cells significantly reduces FGF2- and VEGFA-stimulated cell migration (by ~36% and ~50%) but not proliferation or permeability, with associated elevation of phospholipase C-β3 (PLCβ3) phosphorylation at S537, indicating GNA11 mediates growth factor-induced endothelial migration partially via PLCβ3 regulation.","method":"siRNA knockdown of GNA11 in human umbilical vein endothelial cells, migration/proliferation/permeability assays, phospho-PLCβ3 immunoblotting","journal":"The Journal of physiology","confidence":"Medium","confidence_rationale":"Tier 2 — clean siRNA KD with specific phenotypic readout and signaling mechanism, single lab","pmids":["29659033"],"is_preprint":false},{"year":2022,"finding":"GNAQ and GNA11 encoded G-proteins have different protein interaction partners; specifically, TET2 (a DNA demethylase) physically interacts with GNAQ but not GNA11, suggesting differential regulation of DNA methylation by the two G-proteins.","method":"Tandem-affinity purification, mass spectrometry, immunoprecipitation","journal":"European journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal Co-IP and MS interactome, single lab","pmids":["35580369"],"is_preprint":false},{"year":2023,"finding":"Disease-causing GNAQ/GNA11 mosaic variants hyperactivate constitutive and ligand-induced intracellular calcium signaling in endothelial cells via calcium-release-activated channels; silencing the variant allele with siRNA corrects both constitutive and ligand-activated calcium signaling; calcium-release-activated channel inhibition rescues ligand-activated signal.","method":"Two cellular models of GNAQ/GNA11 mosaic variants, calcium signaling assays, allele-specific siRNA, calcium-release-activated channel inhibitor treatment","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 1 — two cellular models, allele-specific rescue, and pharmacological rescue, multiple orthogonal methods","pmids":["37802293"],"is_preprint":false},{"year":2024,"finding":"INPP5A (an inositol phosphatase that dephosphorylates IP3) is a synthetic lethal dependency in GNAQ/GNA11-mutant uveal melanoma cells; mutant cells produce high IP3 and accumulate IP3 upon INPP5A suppression, leading to hyperactivation of IP3-receptor signaling, increased cytosolic calcium, and p53-dependent apoptosis.","method":"Genome-scale CRISPR screens, computational cancer dependency analyses, in vitro and in vivo cellular assays, IP3/IP4 measurements, Gq/11 inhibitor experiments","journal":"Nature cancer","confidence":"High","confidence_rationale":"Tier 1 — genome-scale CRISPR screen + mechanistic follow-up with signaling measurements + in vivo validation","pmids":["38233483"],"is_preprint":false},{"year":2013,"finding":"The GNA11 promoter contains a functional early growth response 1 (Egr-1) binding site at nt-475/-445; Egr-1 drives >2-fold increase in GNA11 promoter activity and elevates Gα11 mRNA expression, establishing Egr-1 as a transcriptional regulator of GNA11.","method":"Promoter cloning and luciferase reporter assays, electrophoretic mobility shift assay (EMSA), Egr-1 expression plasmid, real-time PCR","journal":"Basic & clinical pharmacology & toxicology","confidence":"Medium","confidence_rationale":"Tier 1 — EMSA binding + reporter assay + mRNA quantification, single lab","pmids":["23802749"],"is_preprint":false},{"year":1996,"finding":"Mouse Gna11 and Gna15 are tandemly duplicated genes on chromosome 10; Gna11 is ubiquitously expressed while Gna15 is hematopoietic-restricted; both genes contain coding sequences across seven exons with conserved intron positions, consistent with origin by tandem duplication from a common progenitor.","method":"Genomic cloning, gene structure analysis, expression pattern analysis, sequence alignment, phylogenetic analysis","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — direct genomic and expression characterization, foundational gene structure paper","pmids":["8838318"],"is_preprint":false},{"year":2024,"finding":"Constitutively active GNA11/GNAQ in uveal melanoma drives sustained IP3 production downstream of PLCβ, but UVM cells downregulate IP3 receptor (IP3R) expression to uncouple IP3 from ER calcium release, protecting against calcium-driven cell death; restoration of IP3R3 expression re-sensitizes UVM cells to apoptosis.","method":"IP3R expression analysis in human UVM tumors, IP3R3 re-expression experiments, apoptosis assays, Gαq/11 inhibitor (FR900359) treatment","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic follow-up in human tumors and cell lines, functional rescue experiment; preprint only","pmids":[],"is_preprint":true},{"year":2024,"finding":"Constitutively active GNA11/GNAQ drives spontaneous calcium oscillations in uveal melanoma cells via constitutive IP3 production; these oscillations are abolished by Gq/11 inhibitor FR900359 and are modulated by INPP5A (which dephosphorylates IP3); INPP5A localization to plasma membrane depends on palmitoylation, while prenylation loss results in nucleoplasmic localization.","method":"Single-cell calcium imaging, Gq/11 inhibitor treatment, INPP5A inhibitor treatment, GFP-tagged INPP5A subcellular localization, palmitoylation and prenylation site mutagenesis","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 — live imaging + pharmacological inhibition + mutagenesis of localization signals; preprint only","pmids":[],"is_preprint":true},{"year":2025,"finding":"In collecting lymphatic vessels, mechano-activation of GNAQ/GNA11-coupled GPCRs generates IP3, which induces SR calcium release through IP3R1 and drives depolarization through ANO1 chloride channels, mediating pressure-induced chronotropy; TRP mechanosensitive channels are not required for this process.","method":"Ex vivo contraction assays, scRNA-seq, transgenic mice with genetic deletion of specific channels, pharmacological inhibitors","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis via transgenic mice + pharmacological validation; preprint only","pmids":[],"is_preprint":true}],"current_model":"GNA11 encodes Gα11, a ubiquitously expressed α-subunit of the Gq-class heterotrimeric G protein that couples GPCRs (notably the calcium-sensing receptor) to phospholipase C-β activation, generating IP3 and DAG; constitutively activating mutations (Q209L/P, R183C/H) drive PKC→RasGRP3→Ras→MAPK signaling and YAP activation in uveal melanoma, while also hyperactivating IP3-mediated calcium signaling that UVM cells counteract by downregulating IP3 receptors; loss-of-function mutations impair CaSR-PLC coupling causing familial hypocalciuric hypercalcemia type 2, and gain-of-function germline mutations cause autosomal dominant hypocalcemia type 2."},"narrative":{"teleology":[{"year":1996,"claim":"Establishing that Gna11 is a ubiquitously expressed Gq-family gene tandemly duplicated with the hematopoietic-restricted Gna15 provided the foundational genomic context for understanding GNA11's broad tissue role versus paralog-specific functions.","evidence":"Genomic cloning, gene structure comparison, and tissue expression analysis in mouse","pmids":["8838318"],"confidence":"Medium","gaps":["No functional data on signaling activity","Relationship to human GNA11 regulation not tested"]},{"year":2010,"claim":"Identification of somatic activating mutations (Q209L/P, R183) in uveal melanoma tumors—with demonstration that mutant GNA11 constitutively activates MAPK and drives metastatic melanoma in mice—established GNA11 as a bona fide oncogene and defined the key oncogenic residues.","evidence":"Tumor sequencing of uveal melanoma cohorts, GNA11-mutant melanocyte mouse model, MAPK pathway assays","pmids":["21083380"],"confidence":"High","gaps":["Mechanism linking Gα11 to MAPK (intermediate effectors) unknown at this point","Role of IP3/calcium arm not yet explored in UVM context"]},{"year":2013,"claim":"Demonstrating that PKC acts upstream of ERK in GNAQ/GNA11-mutant cells resolved the signaling hierarchy: mutant Gα11 activates PLCβ→DAG→PKC, which then drives MAPK, providing a rationale for PKC-targeted therapy.","evidence":"PKC inhibitor (AEB071, AHT956) and MEK inhibitor treatment in mutant vs. wild-type cell lines and xenograft models","pmids":["24141786"],"confidence":"High","gaps":["Identity of the PKC-to-Ras intermediary not yet known","Contribution of IP3/calcium branch to proliferation uncharacterized"]},{"year":2013,"claim":"Identification of Egr-1 as a transcriptional activator of the GNA11 promoter revealed a transcriptional regulatory input that could modulate Gα11 expression levels.","evidence":"Promoter-luciferase reporter, EMSA, Egr-1 overexpression with qPCR readout","pmids":["23802749"],"confidence":"Medium","gaps":["Physiological relevance of Egr-1-driven GNA11 upregulation in vivo not tested","No data on whether this regulation is tissue-specific"]},{"year":2014,"claim":"Functional characterization of a germline gain-of-function GNA11 mutation (R60L) causing autosomal dominant hypocalcemia demonstrated that Gα11 is the critical transducer coupling CaSR to intracellular calcium in parathyroid physiology.","evidence":"Whole-exome sequencing of affected family, mutant Gα11 expressed in HEK293-CaSR cells with quantitative calcium EC50 measurement","pmids":["24823460"],"confidence":"High","gaps":["Structural basis of R60L gain-of-function not resolved","Relative contribution of GNA11 vs. GNAQ to CaSR signaling in parathyroid not dissected"]},{"year":2016,"claim":"Characterization of the loss-of-function T54M mutation causing FHH2 revealed that the Gα11 helical/GTPase domain interface is critical for GDP binding and receptor-coupled signaling, explaining a distinct disease mechanism from gain-of-function alleles.","evidence":"3D homology modeling, functional expression in HEK293-CaSR cells with flow cytometry-based calcium measurement","pmids":["26729423"],"confidence":"High","gaps":["No crystal structure of Gα11 itself; based on homology model","Whether T54M affects GTP binding/hydrolysis kinetics not directly measured"]},{"year":2017,"claim":"Structure-guided mutagenesis of the Gα11 hydrophobic cleft (including the disease-causing F220S mutation) established this surface as the PLCβ-activation interface, mechanistically linking loss-of-function GNA11 mutations to impaired PLC and MAPK signaling in FHH2.","evidence":"Homology modeling, site-directed mutagenesis of hydrophobic cleft residues, intracellular calcium and ERK assays in HEK293-CaSR cells, cinacalcet rescue in vitro and in vivo","pmids":["28833550"],"confidence":"High","gaps":["Direct structural data (co-crystal of Gα11–PLCβ) still lacking","Whether other effectors also engage this cleft not tested"]},{"year":2018,"claim":"Identification of RasGRP3 as the critical intermediate linking PKC/DAG downstream of mutant GNA11 to Ras activation closed the gap between Gα11→PLCβ and MAPK, defining the full oncogenic signaling cascade in uveal melanoma.","evidence":"GNA11(Q209L) transgenic mouse model, integrative transcriptomics, siRNA knockdown in human UVM lines, in vivo tumor assays","pmids":["29490280"],"confidence":"High","gaps":["Whether RasGRP3 is activated by DAG directly or via PKC phosphorylation not fully resolved","Applicability to non-UVM GNA11-mutant tumors not tested"]},{"year":2018,"claim":"Showing that GNA11 knockdown selectively impairs FGF2/VEGFA-stimulated endothelial migration (but not proliferation) via PLCβ3 phosphorylation extended Gα11 function beyond GPCR-canonical signaling to growth factor receptor–coupled endothelial biology.","evidence":"siRNA knockdown in HUVECs, migration/proliferation/permeability assays, phospho-PLCβ3 immunoblotting","pmids":["29659033"],"confidence":"Medium","gaps":["Mechanism by which RTK signaling engages Gα11 is unclear","Single siRNA-based study without genetic rescue"]},{"year":2022,"claim":"Proteomic comparison revealed that GNAQ and GNA11, despite functional overlap in UVM, have distinct protein interaction partners—TET2 binds GNAQ but not GNA11—suggesting paralog-specific effector coupling.","evidence":"Tandem-affinity purification, mass spectrometry, immunoprecipitation","pmids":["35580369"],"confidence":"Medium","gaps":["Functional consequence of differential TET2 interaction not tested","No reciprocal GNA11-specific interactors highlighted"]},{"year":2023,"claim":"Demonstrating that mosaic activating GNA11/GNAQ variants hyperactivate calcium signaling through calcium-release-activated channels, and that allele-specific siRNA or CRAC inhibition rescues this, established a calcium-centric pathomechanism for Sturge-Weber-like vascular anomalies and identified a druggable target.","evidence":"Two cellular models of mosaic variants, calcium imaging, allele-specific siRNA, CRAC channel inhibitor","pmids":["37802293"],"confidence":"High","gaps":["In vivo validation of CRAC inhibition in vascular malformation models not shown","Relative contribution of IP3R vs. CRAC to pathology not fully resolved"]},{"year":2024,"claim":"Genome-scale CRISPR screens identified INPP5A as a synthetic lethal dependency in GNA11/GNAQ-mutant UVM, revealing that mutant cells depend on IP3 metabolism to prevent IP3R-mediated calcium overload and p53-dependent apoptosis—mechanistically separating the IP3/calcium toxicity arm from the pro-proliferative MAPK arm.","evidence":"Genome-scale CRISPR screen, IP3/IP4 measurements, calcium assays, Gq/11 inhibitor, in vivo xenograft validation","pmids":["38233483"],"confidence":"High","gaps":["Clinical translatability of INPP5A targeting not established","Whether p53-independent death pathways also contribute is unclear"]},{"year":null,"claim":"Key unresolved questions include the direct structural basis of Gα11–PLCβ engagement (no Gα11 co-crystal exists), the mechanism by which Gα11 couples to RTK-driven migration, and whether paralog-specific interactors of GNA11 (distinct from GNAQ) mediate non-overlapping physiological functions.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of Gα11 alone or in complex with PLCβ","Mechanism of Gα11 engagement by growth factor receptor signaling unresolved","Paralog-specific effectors of GNA11 versus GNAQ not functionally characterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[0,3,5]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,5,6,10]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2,5,9]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,5,9]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2,5,6,9,10]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,6,10]}],"complexes":["heterotrimeric Gq protein (Gα11/β/γ)"],"partners":["GNAQ","PLCB3","RASGRP3","INPP5A","CASR"],"other_free_text":[]},"mechanistic_narrative":"GNA11 encodes Gα11, a ubiquitously expressed α-subunit of the Gq class of heterotrimeric G proteins that couples GPCRs—most notably the calcium-sensing receptor (CaSR)—to phospholipase C-β (PLCβ) activation, generating IP3 and diacylglycerol to drive intracellular calcium mobilization and MAPK signaling [PMID:28833550, PMID:24823460]. Somatic activating mutations at Q209 and R183 constitutively activate PLCβ, leading to sustained IP3 production and PKC-dependent activation of RasGRP3→Ras→MAPK signaling, establishing GNA11 as a major oncogenic driver in uveal melanoma; tumor cells compensate for chronic IP3 overproduction by downregulating IP3 receptors, and disruption of the IP3-metabolizing phosphatase INPP5A is synthetically lethal in these cells [PMID:21083380, PMID:24141786, PMID:29490280, PMID:38233483]. Germline gain-of-function mutations (e.g., R60L) cause autosomal dominant hypocalcemia type 2 by sensitizing CaSR-Gα11-PLCβ calcium signaling, whereas loss-of-function mutations (e.g., T54M, F220S) that impair GDP binding or the PLCβ-activating hydrophobic cleft cause familial hypocalciuric hypercalcemia type 2 [PMID:24823460, PMID:26729423, PMID:28833550]. GNA11 also mediates growth factor–induced endothelial cell migration through regulation of PLCβ3 phosphorylation [PMID:29659033]."},"prefetch_data":{"uniprot":{"accession":"P29992","full_name":"Guanine nucleotide-binding protein subunit alpha-11","aliases":["Guanine nucleotide-binding protein G(y) subunit alpha"],"length_aa":359,"mass_kda":42.1,"function":"Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades (PubMed:31073061). The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state (PubMed:31073061). Signaling by an activated GPCR promotes GDP release and GTP binding (PubMed:31073061). The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal (PubMed:31073061). Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins (PubMed:31073061). Signaling is mediated via phospholipase C-beta-dependent inositol lipid hydrolysis for signal propagation: activates phospholipase C-beta: following GPCR activation, GNA11 activates PLC-beta (PLCB1, PLCB2, PLCB3 or PLCB4), leading to production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) (PubMed:31073061). Transduces FFAR4 signaling in response to long-chain fatty acids (LCFAs) (PubMed:27852822). Together with GNAQ, required for heart development (By similarity). In the respiratory epithelium, transmits OXGR1-dependent signals that lead to downstream intracellular Ca(2+) release and mucocilliary clearance of airborne pathogens","subcellular_location":"Cell membrane; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P29992/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GNA11","classification":"Not Classified","n_dependent_lines":10,"n_total_lines":1208,"dependency_fraction":0.008278145695364239},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"GNB1","stoichiometry":10.0},{"gene":"RAB11A","stoichiometry":0.2},{"gene":"SLC16A1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/GNA11","total_profiled":1310},"omim":[{"mim_id":"620874","title":"ADHESION G PROTEIN-COUPLED RECEPTOR F5; ADGRF5","url":"https://www.omim.org/entry/620874"},{"mim_id":"618448","title":"G PROTEIN-COUPLED RECEPTOR 139; GPR139","url":"https://www.omim.org/entry/618448"},{"mim_id":"615706","title":"AURICULOCONDYLAR SYNDROME 3; ARCND3","url":"https://www.omim.org/entry/615706"},{"mim_id":"615650","title":"REGULATOR OF G PROTEIN SIGNALING 22; RGS22","url":"https://www.omim.org/entry/615650"},{"mim_id":"615361","title":"HYPOCALCEMIA, AUTOSOMAL DOMINANT 2; HYPOC2","url":"https://www.omim.org/entry/615361"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GNA11"},"hgnc":{"alias_symbol":["FBH","FBH2","FHH2"],"prev_symbol":["HHC2"]},"alphafold":{"accession":"P29992","domains":[{"cath_id":"3.40.50.300","chopping":"44-66_186-349","consensus_level":"medium","plddt":94.8433,"start":44,"end":349},{"cath_id":"1.10.400.10","chopping":"68-180","consensus_level":"medium","plddt":97.615,"start":68,"end":180}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P29992","model_url":"https://alphafold.ebi.ac.uk/files/AF-P29992-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P29992-F1-predicted_aligned_error_v6.png","plddt_mean":92.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GNA11","jax_strain_url":"https://www.jax.org/strain/search?query=GNA11"},"sequence":{"accession":"P29992","fasta_url":"https://rest.uniprot.org/uniprotkb/P29992.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P29992/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P29992"}},"corpus_meta":[{"pmid":"21083380","id":"PMC_21083380","title":"Mutations in GNA11 in uveal melanoma.","date":"2010","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21083380","citation_count":1162,"is_preprint":false},{"pmid":"24141786","id":"PMC_24141786","title":"Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24141786","citation_count":162,"is_preprint":false},{"pmid":"26778290","id":"PMC_26778290","title":"Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis.","date":"2016","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/26778290","citation_count":127,"is_preprint":false},{"pmid":"27058448","id":"PMC_27058448","title":"Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27058448","citation_count":125,"is_preprint":false},{"pmid":"22733540","id":"PMC_22733540","title":"Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.","date":"2012","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/22733540","citation_count":120,"is_preprint":false},{"pmid":"28120216","id":"PMC_28120216","title":"A somatic GNA11 mutation is associated with extremity capillary malformation and overgrowth.","date":"2017","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28120216","citation_count":108,"is_preprint":false},{"pmid":"25304237","id":"PMC_25304237","title":"GNAQ and GNA11 mutations in uveal melanoma.","date":"2014","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/25304237","citation_count":97,"is_preprint":false},{"pmid":"26645730","id":"PMC_26645730","title":"Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp.","date":"2016","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26645730","citation_count":92,"is_preprint":false},{"pmid":"24423917","id":"PMC_24423917","title":"Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma.","date":"2014","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24423917","citation_count":86,"is_preprint":false},{"pmid":"23778528","id":"PMC_23778528","title":"Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11.","date":"2013","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23778528","citation_count":83,"is_preprint":false},{"pmid":"28809862","id":"PMC_28809862","title":"GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi.","date":"2017","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28809862","citation_count":74,"is_preprint":false},{"pmid":"12736724","id":"PMC_12736724","title":"FNBP2 gene on human chromosome 1q32.1 encodes ARHGAP family protein with FCH, FBH, RhoGAP and SH3 domains.","date":"2003","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12736724","citation_count":71,"is_preprint":false},{"pmid":"29490280","id":"PMC_29490280","title":"GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29490280","citation_count":69,"is_preprint":false},{"pmid":"34385710","id":"PMC_34385710","title":"Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause.","date":"2021","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34385710","citation_count":66,"is_preprint":false},{"pmid":"24823460","id":"PMC_24823460","title":"Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization.","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24823460","citation_count":63,"is_preprint":false},{"pmid":"12759536","id":"PMC_12759536","title":"Reduced expression of GNA11 and silencing of MCT1 in human breast cancers.","date":"2003","source":"Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12759536","citation_count":55,"is_preprint":false},{"pmid":"26399561","id":"PMC_26399561","title":"Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.","date":"2015","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26399561","citation_count":53,"is_preprint":false},{"pmid":"24563540","id":"PMC_24563540","title":"The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.","date":"2014","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24563540","citation_count":53,"is_preprint":false},{"pmid":"22758774","id":"PMC_22758774","title":"GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system.","date":"2013","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/22758774","citation_count":47,"is_preprint":false},{"pmid":"30204251","id":"PMC_30204251","title":"GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers.","date":"2018","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30204251","citation_count":43,"is_preprint":false},{"pmid":"23634288","id":"PMC_23634288","title":"Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma.","date":"2013","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23634288","citation_count":42,"is_preprint":false},{"pmid":"27914687","id":"PMC_27914687","title":"BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.","date":"2016","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27914687","citation_count":39,"is_preprint":false},{"pmid":"31189994","id":"PMC_31189994","title":"High frequency of GNA14, GNAQ, and GNA11 mutations in cherry hemangioma: a histopathological and molecular study of 85 cases indicating GNA14 as the most commonly mutated gene in vascular neoplasms.","date":"2019","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/31189994","citation_count":38,"is_preprint":false},{"pmid":"26729423","id":"PMC_26729423","title":"A G-protein Subunit-α11 Loss-of-Function Mutation, Thr54Met, Causes Familial Hypocalciuric Hypercalcemia Type 2 (FHH2).","date":"2016","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/26729423","citation_count":36,"is_preprint":false},{"pmid":"28700778","id":"PMC_28700778","title":"Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.","date":"2017","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/28700778","citation_count":35,"is_preprint":false},{"pmid":"28833550","id":"PMC_28833550","title":"Cinacalcet Rectifies Hypercalcemia in a Patient With Familial Hypocalciuric Hypercalcemia Type 2 (FHH2) Caused by a Germline Loss-of-Function Gα11 Mutation.","date":"2017","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/28833550","citation_count":34,"is_preprint":false},{"pmid":"27438697","id":"PMC_27438697","title":"Symptomatic Congenital Hemangioma and Congenital Hemangiomatosis Associated With a Somatic Activating Mutation in GNA11.","date":"2016","source":"JAMA dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/27438697","citation_count":33,"is_preprint":false},{"pmid":"26368812","id":"PMC_26368812","title":"Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26368812","citation_count":33,"is_preprint":false},{"pmid":"23599145","id":"PMC_23599145","title":"Identification of HRAS mutations and absence of GNAQ or GNA11 mutations in deep penetrating nevi.","date":"2013","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/23599145","citation_count":32,"is_preprint":false},{"pmid":"32064597","id":"PMC_32064597","title":"GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.","date":"2020","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/32064597","citation_count":31,"is_preprint":false},{"pmid":"33604650","id":"PMC_33604650","title":"The Arabidopsis histone demethylase JMJ28 regulates CONSTANS by interacting with FBH transcription factors.","date":"2021","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/33604650","citation_count":31,"is_preprint":false},{"pmid":"27148356","id":"PMC_27148356","title":"Gnaq and Gna11 in the Endothelin Signaling Pathway and Melanoma.","date":"2016","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27148356","citation_count":29,"is_preprint":false},{"pmid":"31707589","id":"PMC_31707589","title":"GNA11 joins GNAQ and GNA14 as a recurrently mutated gene in anastomosing hemangioma.","date":"2019","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31707589","citation_count":28,"is_preprint":false},{"pmid":"30763678","id":"PMC_30763678","title":"Ubiquitylome profiling of Parkin-null brain reveals dysregulation of calcium homeostasis factors ATP1A2, Hippocalcin and GNA11, reflected by altered firing of noradrenergic neurons.","date":"2019","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/30763678","citation_count":27,"is_preprint":false},{"pmid":"35715928","id":"PMC_35715928","title":"GNA11-mutated Sturge-Weber syndrome has distinct neurological and dermatological features.","date":"2022","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35715928","citation_count":26,"is_preprint":false},{"pmid":"8838318","id":"PMC_8838318","title":"Gene structure of murine Gna11 and Gna15: tandemly duplicated Gq class G protein alpha subunit genes.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8838318","citation_count":25,"is_preprint":false},{"pmid":"25280020","id":"PMC_25280020","title":"Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25280020","citation_count":23,"is_preprint":false},{"pmid":"35580369","id":"PMC_35580369","title":"In uveal melanoma Gα-protein GNA11 mutations convey a shorter disease-specific survival and are more strongly associated with loss of BAP1 and chromosomal alterations than Gα-protein GNAQ mutations.","date":"2022","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/35580369","citation_count":23,"is_preprint":false},{"pmid":"27308390","id":"PMC_27308390","title":"YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.","date":"2014","source":"Molecular & cellular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27308390","citation_count":22,"is_preprint":false},{"pmid":"34040639","id":"PMC_34040639","title":"GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34040639","citation_count":22,"is_preprint":false},{"pmid":"31173078","id":"PMC_31173078","title":"Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.","date":"2019","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/31173078","citation_count":22,"is_preprint":false},{"pmid":"29209985","id":"PMC_29209985","title":"Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.","date":"2017","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/29209985","citation_count":21,"is_preprint":false},{"pmid":"27334330","id":"PMC_27334330","title":"Impaired growth and intracranial calcifications in autosomal dominant hypocalcemia caused by a GNA11 mutation.","date":"2016","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27334330","citation_count":17,"is_preprint":false},{"pmid":"28176280","id":"PMC_28176280","title":"Stepwise CaSR, AP2S1, and GNA11 sequencing in patients with suspected familial hypocalciuric hypercalcemia.","date":"2017","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/28176280","citation_count":17,"is_preprint":false},{"pmid":"27913609","id":"PMC_27913609","title":"AP2S1 and GNA11 mutations - not a common cause of familial hypocalciuric hypercalcemia.","date":"2016","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27913609","citation_count":16,"is_preprint":false},{"pmid":"31614358","id":"PMC_31614358","title":"Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients.","date":"2019","source":"Ophthalmic research","url":"https://pubmed.ncbi.nlm.nih.gov/31614358","citation_count":16,"is_preprint":false},{"pmid":"29514290","id":"PMC_29514290","title":"The FBH family of bHLH transcription factors controls ACC synthase expression in sugarcane.","date":"2018","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/29514290","citation_count":14,"is_preprint":false},{"pmid":"37802293","id":"PMC_37802293","title":"GNAQ/GNA11 Mosaicism Causes Aberrant Calcium Signaling Susceptible to Targeted Therapeutics.","date":"2023","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/37802293","citation_count":14,"is_preprint":false},{"pmid":"23825798","id":"PMC_23825798","title":"Lack of GNAQ and GNA11 Germ-Line Mutations in Familial Melanoma Pedigrees with Uveal Melanoma or Blue Nevi.","date":"2013","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23825798","citation_count":13,"is_preprint":false},{"pmid":"23650591","id":"PMC_23650591","title":"BRAF, GNAQ, and GNA11 mutations and copy number in pediatric low-grade glioma.","date":"2012","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/23650591","citation_count":12,"is_preprint":false},{"pmid":"28881731","id":"PMC_28881731","title":"Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28881731","citation_count":12,"is_preprint":false},{"pmid":"31394807","id":"PMC_31394807","title":"Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma?","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31394807","citation_count":12,"is_preprint":false},{"pmid":"38233483","id":"PMC_38233483","title":"INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas.","date":"2024","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38233483","citation_count":11,"is_preprint":false},{"pmid":"27239460","id":"PMC_27239460","title":"Investigation of Somatic GNAQ, GNA11, BAP1 and SF3B1 Mutations in Ophthalmic Melanocytomas.","date":"2016","source":"Ocular oncology and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27239460","citation_count":11,"is_preprint":false},{"pmid":"24137342","id":"PMC_24137342","title":"Mutational analysis of the GNA11, MMP27, FGD1, TRRAP and GRM3 genes in thyroid cancer.","date":"2013","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/24137342","citation_count":11,"is_preprint":false},{"pmid":"32310862","id":"PMC_32310862","title":"Melanoma Ex Blue Nevus With GNA11 Mutation and BAP1 Loss: Case Report and Review of the Literature.","date":"2020","source":"The American Journal of dermatopathology","url":"https://pubmed.ncbi.nlm.nih.gov/32310862","citation_count":11,"is_preprint":false},{"pmid":"36970776","id":"PMC_36970776","title":"GNA11 Variants Identified in Patients with Hypercalcemia or Hypocalcemia.","date":"2023","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/36970776","citation_count":10,"is_preprint":false},{"pmid":"26275246","id":"PMC_26275246","title":"BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population.","date":"2015","source":"Indian journal of pathology & microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/26275246","citation_count":9,"is_preprint":false},{"pmid":"31310691","id":"PMC_31310691","title":"Oral pyogenic granulomas show MAPK/ERK signaling pathway activation, which occurs independently of BRAF, KRAS, HRAS, NRAS, GNA11, and GNA14 mutations.","date":"2019","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31310691","citation_count":9,"is_preprint":false},{"pmid":"18330691","id":"PMC_18330691","title":"Cloning, expression pattern, chromosomal localization, and evolution analysis of Porcine gnaq, gna11, and gna14.","date":"2008","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18330691","citation_count":9,"is_preprint":false},{"pmid":"26825879","id":"PMC_26825879","title":"GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report.","date":"2016","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26825879","citation_count":9,"is_preprint":false},{"pmid":"37750536","id":"PMC_37750536","title":"Papillary Hemangioma Harbors Somatic GNA11 and GNAQ Mutations.","date":"2023","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37750536","citation_count":8,"is_preprint":false},{"pmid":"35351629","id":"PMC_35351629","title":"Cutis marmorata telangiectatica congenita being caused by postzygotic GNA11 mutations.","date":"2022","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35351629","citation_count":8,"is_preprint":false},{"pmid":"28982892","id":"PMC_28982892","title":"Uveal Melanoma: GNAQ and GNA11 Mutations in a Greek Population.","date":"2017","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28982892","citation_count":8,"is_preprint":false},{"pmid":"29659033","id":"PMC_29659033","title":"GNA11 differentially mediates fibroblast growth factor 2- and vascular endothelial growth factor A-induced cellular responses in human fetoplacental endothelial cells.","date":"2018","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29659033","citation_count":8,"is_preprint":false},{"pmid":"34345456","id":"PMC_34345456","title":"S-100-negative, GNA11 mutation-positive intramedullary meningeal melanocytoma of the thoracic spine: A radiographic challenge and histologic anomaly.","date":"2021","source":"Surgical neurology international","url":"https://pubmed.ncbi.nlm.nih.gov/34345456","citation_count":7,"is_preprint":false},{"pmid":"34750314","id":"PMC_34750314","title":"GNA11 Mutation in an Intracranial Melanocytoma with Orbital Involvement and Nevus of Ota.","date":"2022","source":"Ophthalmic plastic and reconstructive surgery","url":"https://pubmed.ncbi.nlm.nih.gov/34750314","citation_count":6,"is_preprint":false},{"pmid":"28248732","id":"PMC_28248732","title":"The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan.","date":"2018","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/28248732","citation_count":6,"is_preprint":false},{"pmid":"24797109","id":"PMC_24797109","title":"Subcellular distribution patterns and elevated expression of GNA11 and GNA14 proteins in the lungs of humans with pulmonary arterial hypertension.","date":"2014","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/24797109","citation_count":6,"is_preprint":false},{"pmid":"38505749","id":"PMC_38505749","title":"Double somatic mutations in CTNNB1 and GNA11 in an aldosterone-producing adenoma.","date":"2024","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/38505749","citation_count":5,"is_preprint":false},{"pmid":"35693877","id":"PMC_35693877","title":"Mutation spectrum in GNAQ and GNA11 in Chinese uveal melanoma.","date":"2019","source":"Precision clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35693877","citation_count":5,"is_preprint":false},{"pmid":"35642348","id":"PMC_35642348","title":"BRAF, NRAS, KIT, TERT, GNAQ/GNA11 Mutation Profile and Histomorphological Analysis of Anorectal Melanomas: A Clinicopathologic Study.","date":"2023","source":"Turk patoloji dergisi","url":"https://pubmed.ncbi.nlm.nih.gov/35642348","citation_count":4,"is_preprint":false},{"pmid":"36835134","id":"PMC_36835134","title":"Autoantibodies to PAX5, PTCH1, and GNA11 as Serological Biomarkers in the Detection of Hepatocellular Carcinoma in Hispanic Americans.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36835134","citation_count":4,"is_preprint":false},{"pmid":"34568004","id":"PMC_34568004","title":"Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34568004","citation_count":4,"is_preprint":false},{"pmid":"23464620","id":"PMC_23464620","title":"Skin metastases in metastatic uveal melanoma: GNAQ/GNA11 mutational analysis as a valuable tool.","date":"2013","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/23464620","citation_count":4,"is_preprint":false},{"pmid":"23802749","id":"PMC_23802749","title":"Cloning and characterization of the GNA11 promoter and its regulation by early growth response 1.","date":"2013","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/23802749","citation_count":3,"is_preprint":false},{"pmid":"34260077","id":"PMC_34260077","title":"Mixed vascular naevus syndrome: report of three children with somatic GNA11 mutation and new systemic associations.","date":"2021","source":"Clinical and experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/34260077","citation_count":3,"is_preprint":false},{"pmid":"35777808","id":"PMC_35777808","title":"The Youngest Infant to Be Diagnosed with Autosomal Dominant Hypocalcemia Type 2 Harboring a Novel Variant of GNA11: A Case Study and Literature Review.","date":"2022","source":"Annals of clinical and laboratory science","url":"https://pubmed.ncbi.nlm.nih.gov/35777808","citation_count":3,"is_preprint":false},{"pmid":"28012237","id":"PMC_28012237","title":"Sporadic melanotic schwannoma with overlapping features of melanocytoma bearing a GNA11 mutation in an adolescent girl.","date":"2016","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28012237","citation_count":3,"is_preprint":false},{"pmid":"39654261","id":"PMC_39654261","title":"Phenotypic Spectrum of GNA11 R183C Mosaicism.","date":"2024","source":"Pediatric dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/39654261","citation_count":2,"is_preprint":false},{"pmid":"38910853","id":"PMC_38910853","title":"Somatic GNA11/GNAQ variants in a cohort of Chinese children with phakomatosis pigmentovascularis.","date":"2024","source":"Pediatric investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38910853","citation_count":1,"is_preprint":false},{"pmid":"41403972","id":"PMC_41403972","title":"Uveal Melanocytoma without GNAQ/GNA11 Mutations.","date":"2025","source":"Ocular oncology and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/41403972","citation_count":0,"is_preprint":false},{"pmid":"37284406","id":"PMC_37284406","title":"Primary Mucosal Melanoma of the Lip With GNA11 Mutation in a 23-Year-Old Pregnant Woman.","date":"2023","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/37284406","citation_count":0,"is_preprint":false},{"pmid":"41240382","id":"PMC_41240382","title":"A novel homozygous c.301T > C, p.Y101H variant in the GNA11 gene is implicated in familial hypocalciuric hypercalcemia type 2 in a proband with the heterozygous variant present in mother and father - A case report.","date":"2025","source":"Scandinavian journal of clinical and laboratory investigation","url":"https://pubmed.ncbi.nlm.nih.gov/41240382","citation_count":0,"is_preprint":false},{"pmid":"31887832","id":"PMC_31887832","title":"[GNA11 gene rs11084997 polymorphisms might be associated with risk of adult-onset non-surgical hypoparathyroidism].","date":"2020","source":"Zhonghua nei ke za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/31887832","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.07.681001","title":"Roles of G-protein coupled receptors and mechanosensitive ion channels in pressure-induced chronotropy of lymphatic vessels","date":"2025-10-07","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.07.681001","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.04.652102","title":"Context-Dependent Synergism and Antagonism between IGF2BP1/3 and METTL3/14 in m6A-mediated mRNA regulation","date":"2025-05-04","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.04.652102","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.24.633441","title":"Clinico-genomic features predict distinct metastatic phenotypes in cutaneous melanoma","date":"2025-01-27","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.24.633441","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.25.625282","title":"Oncogenic GNAQ/11-induced remodeling of the IP3/Calcium signaling pathway protects Uveal Melanoma against Calcium-driven cell death","date":"2024-11-28","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.25.625282","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.18.613756","title":"Examination of INPP5A in uveal melanoma uncovers novel calcium transients","date":"2024-09-22","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.18.613756","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48568,"output_tokens":3804,"usd":0.101382},"stage2":{"model":"claude-opus-4-6","input_tokens":7247,"output_tokens":3236,"usd":0.175703},"total_usd":0.277085,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"Somatic activating mutations in GNA11 (Q209L/P at codon 209, R183 at exon 4) constitutively activate the MAPK pathway and induce spontaneously metastasizing tumors in a mouse model, establishing GNA11 as an oncogenic driver in uveal melanoma.\",\n      \"method\": \"Tumor sequencing, mouse model with GNA11-mutant melanocytes, MAPK pathway assays\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo mouse model + pathway activation assay, highly cited foundational study\",\n      \"pmids\": [\"21083380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GNAQ or GNA11 mutation consistently activates both PKC and MAPK pathways in uveal melanoma; PKC acts upstream of MAPK activation, as PKC inhibition suppresses ERK signaling selectively in GNAQ/GNA11-mutant cells.\",\n      \"method\": \"PKC inhibitor treatment (AEB071, AHT956), MEK inhibitor treatment, signaling assays in mutant vs. wild-type cell lines, xenograft tumor models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple inhibitors, in vitro and in vivo, epistasis demonstrated by pathway assays\",\n      \"pmids\": [\"24141786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Germline gain-of-function GNA11 mutation (R60L) causes autosomal dominant hypoparathyroidism by increasing intracellular calcium accumulation in response to extracellular calcium with decreased EC50, demonstrating GNA11 couples the calcium-sensing receptor (CaSR) to intracellular calcium signaling in parathyroid cells.\",\n      \"method\": \"Whole-exome sequencing, functional expression of mutant Gα11 R60L in HEK293-CaR cells, intracellular calcium concentration measurement\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro functional reconstitution with mutant protein in CaSR-expressing cells, quantitative EC50 measurement\",\n      \"pmids\": [\"24823460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Loss-of-function GNA11 mutation (Thr54Met), located at the interface between the Gα11 helical and GTPase domains, impairs GDP binding and interdomain interactions, resulting in reduced CaSR-mediated intracellular calcium signaling (rightward shift of concentration-response curve), causing familial hypocalciuric hypercalcemia type 2 (FHH2).\",\n      \"method\": \"3D homology modeling of Gα11, functional expression in HEK293-CaSR cells, flow cytometry-based intracellular calcium measurement\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural modeling + in vitro functional assay with quantitative signaling measurement\",\n      \"pmids\": [\"26729423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In vitro expression of mutant GNA11(R183C) activates downstream p38 MAPK signaling pathway, while GNA11(Q209L) activates p38, JNK, and ERK pathways in human cell lines.\",\n      \"method\": \"Transient expression of mutant GNA11 in human cell lines, pathway signaling assays; transgenic mosaic zebrafish model\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro cell expression plus in vivo zebrafish model, single lab\",\n      \"pmids\": [\"26778290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GNA11 loss-of-function mutation Phe220Ser disrupts a hydrophobic cleft region critical for activation of phospholipase C (PLC); mutant Gα11 impairs CaSR-mediated intracellular calcium and ERK MAPK signaling, consistent with diminished PLC activation. Engineered mutagenesis of the hydrophobic cleft confirmed its role in PLC signaling.\",\n      \"method\": \"Homology modeling, transient transfection of mutant Gα11 in HEK293-CaSR cells, intracellular calcium and ERK signaling assays, site-directed mutagenesis of hydrophobic cleft residues, cinacalcet rescue in vitro and in vivo\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-guided mutagenesis + in vitro functional reconstitution + in vivo validation\",\n      \"pmids\": [\"28833550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GNA11(Q209L)-driven uveal melanoma requires RasGRP3 for GNAQ/GNA11-driven Ras activation and tumorigenesis; RasGRP3 is a critical signaling node downstream of mutant GNA11/GNAQ linking G protein activation to Ras/MAPK signaling.\",\n      \"method\": \"GNA11(Q209L) transgenic mouse model, integrative transcriptome analysis of human and murine melanomas, siRNA knockdown in human UM cell lines, in vivo tumor models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic mouse model + human cell line knockdown + transcriptome analysis, replicated in murine and human systems\",\n      \"pmids\": [\"29490280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GNA11 knockdown in fetoplacental endothelial cells significantly reduces FGF2- and VEGFA-stimulated cell migration (by ~36% and ~50%) but not proliferation or permeability, with associated elevation of phospholipase C-β3 (PLCβ3) phosphorylation at S537, indicating GNA11 mediates growth factor-induced endothelial migration partially via PLCβ3 regulation.\",\n      \"method\": \"siRNA knockdown of GNA11 in human umbilical vein endothelial cells, migration/proliferation/permeability assays, phospho-PLCβ3 immunoblotting\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean siRNA KD with specific phenotypic readout and signaling mechanism, single lab\",\n      \"pmids\": [\"29659033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GNAQ and GNA11 encoded G-proteins have different protein interaction partners; specifically, TET2 (a DNA demethylase) physically interacts with GNAQ but not GNA11, suggesting differential regulation of DNA methylation by the two G-proteins.\",\n      \"method\": \"Tandem-affinity purification, mass spectrometry, immunoprecipitation\",\n      \"journal\": \"European journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP and MS interactome, single lab\",\n      \"pmids\": [\"35580369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Disease-causing GNAQ/GNA11 mosaic variants hyperactivate constitutive and ligand-induced intracellular calcium signaling in endothelial cells via calcium-release-activated channels; silencing the variant allele with siRNA corrects both constitutive and ligand-activated calcium signaling; calcium-release-activated channel inhibition rescues ligand-activated signal.\",\n      \"method\": \"Two cellular models of GNAQ/GNA11 mosaic variants, calcium signaling assays, allele-specific siRNA, calcium-release-activated channel inhibitor treatment\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — two cellular models, allele-specific rescue, and pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"37802293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"INPP5A (an inositol phosphatase that dephosphorylates IP3) is a synthetic lethal dependency in GNAQ/GNA11-mutant uveal melanoma cells; mutant cells produce high IP3 and accumulate IP3 upon INPP5A suppression, leading to hyperactivation of IP3-receptor signaling, increased cytosolic calcium, and p53-dependent apoptosis.\",\n      \"method\": \"Genome-scale CRISPR screens, computational cancer dependency analyses, in vitro and in vivo cellular assays, IP3/IP4 measurements, Gq/11 inhibitor experiments\",\n      \"journal\": \"Nature cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — genome-scale CRISPR screen + mechanistic follow-up with signaling measurements + in vivo validation\",\n      \"pmids\": [\"38233483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The GNA11 promoter contains a functional early growth response 1 (Egr-1) binding site at nt-475/-445; Egr-1 drives >2-fold increase in GNA11 promoter activity and elevates Gα11 mRNA expression, establishing Egr-1 as a transcriptional regulator of GNA11.\",\n      \"method\": \"Promoter cloning and luciferase reporter assays, electrophoretic mobility shift assay (EMSA), Egr-1 expression plasmid, real-time PCR\",\n      \"journal\": \"Basic & clinical pharmacology & toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — EMSA binding + reporter assay + mRNA quantification, single lab\",\n      \"pmids\": [\"23802749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Mouse Gna11 and Gna15 are tandemly duplicated genes on chromosome 10; Gna11 is ubiquitously expressed while Gna15 is hematopoietic-restricted; both genes contain coding sequences across seven exons with conserved intron positions, consistent with origin by tandem duplication from a common progenitor.\",\n      \"method\": \"Genomic cloning, gene structure analysis, expression pattern analysis, sequence alignment, phylogenetic analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct genomic and expression characterization, foundational gene structure paper\",\n      \"pmids\": [\"8838318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Constitutively active GNA11/GNAQ in uveal melanoma drives sustained IP3 production downstream of PLCβ, but UVM cells downregulate IP3 receptor (IP3R) expression to uncouple IP3 from ER calcium release, protecting against calcium-driven cell death; restoration of IP3R3 expression re-sensitizes UVM cells to apoptosis.\",\n      \"method\": \"IP3R expression analysis in human UVM tumors, IP3R3 re-expression experiments, apoptosis assays, Gαq/11 inhibitor (FR900359) treatment\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic follow-up in human tumors and cell lines, functional rescue experiment; preprint only\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Constitutively active GNA11/GNAQ drives spontaneous calcium oscillations in uveal melanoma cells via constitutive IP3 production; these oscillations are abolished by Gq/11 inhibitor FR900359 and are modulated by INPP5A (which dephosphorylates IP3); INPP5A localization to plasma membrane depends on palmitoylation, while prenylation loss results in nucleoplasmic localization.\",\n      \"method\": \"Single-cell calcium imaging, Gq/11 inhibitor treatment, INPP5A inhibitor treatment, GFP-tagged INPP5A subcellular localization, palmitoylation and prenylation site mutagenesis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — live imaging + pharmacological inhibition + mutagenesis of localization signals; preprint only\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In collecting lymphatic vessels, mechano-activation of GNAQ/GNA11-coupled GPCRs generates IP3, which induces SR calcium release through IP3R1 and drives depolarization through ANO1 chloride channels, mediating pressure-induced chronotropy; TRP mechanosensitive channels are not required for this process.\",\n      \"method\": \"Ex vivo contraction assays, scRNA-seq, transgenic mice with genetic deletion of specific channels, pharmacological inhibitors\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis via transgenic mice + pharmacological validation; preprint only\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"GNA11 encodes Gα11, a ubiquitously expressed α-subunit of the Gq-class heterotrimeric G protein that couples GPCRs (notably the calcium-sensing receptor) to phospholipase C-β activation, generating IP3 and DAG; constitutively activating mutations (Q209L/P, R183C/H) drive PKC→RasGRP3→Ras→MAPK signaling and YAP activation in uveal melanoma, while also hyperactivating IP3-mediated calcium signaling that UVM cells counteract by downregulating IP3 receptors; loss-of-function mutations impair CaSR-PLC coupling causing familial hypocalciuric hypercalcemia type 2, and gain-of-function germline mutations cause autosomal dominant hypocalcemia type 2.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"GNA11 encodes Gα11, a ubiquitously expressed α-subunit of the Gq class of heterotrimeric G proteins that couples GPCRs—most notably the calcium-sensing receptor (CaSR)—to phospholipase C-β (PLCβ) activation, generating IP3 and diacylglycerol to drive intracellular calcium mobilization and MAPK signaling [PMID:28833550, PMID:24823460]. Somatic activating mutations at Q209 and R183 constitutively activate PLCβ, leading to sustained IP3 production and PKC-dependent activation of RasGRP3→Ras→MAPK signaling, establishing GNA11 as a major oncogenic driver in uveal melanoma; tumor cells compensate for chronic IP3 overproduction by downregulating IP3 receptors, and disruption of the IP3-metabolizing phosphatase INPP5A is synthetically lethal in these cells [PMID:21083380, PMID:24141786, PMID:29490280, PMID:38233483]. Germline gain-of-function mutations (e.g., R60L) cause autosomal dominant hypocalcemia type 2 by sensitizing CaSR-Gα11-PLCβ calcium signaling, whereas loss-of-function mutations (e.g., T54M, F220S) that impair GDP binding or the PLCβ-activating hydrophobic cleft cause familial hypocalciuric hypercalcemia type 2 [PMID:24823460, PMID:26729423, PMID:28833550]. GNA11 also mediates growth factor–induced endothelial cell migration through regulation of PLCβ3 phosphorylation [PMID:29659033].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Establishing that Gna11 is a ubiquitously expressed Gq-family gene tandemly duplicated with the hematopoietic-restricted Gna15 provided the foundational genomic context for understanding GNA11's broad tissue role versus paralog-specific functions.\",\n      \"evidence\": \"Genomic cloning, gene structure comparison, and tissue expression analysis in mouse\",\n      \"pmids\": [\"8838318\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional data on signaling activity\", \"Relationship to human GNA11 regulation not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of somatic activating mutations (Q209L/P, R183) in uveal melanoma tumors—with demonstration that mutant GNA11 constitutively activates MAPK and drives metastatic melanoma in mice—established GNA11 as a bona fide oncogene and defined the key oncogenic residues.\",\n      \"evidence\": \"Tumor sequencing of uveal melanoma cohorts, GNA11-mutant melanocyte mouse model, MAPK pathway assays\",\n      \"pmids\": [\"21083380\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking Gα11 to MAPK (intermediate effectors) unknown at this point\", \"Role of IP3/calcium arm not yet explored in UVM context\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that PKC acts upstream of ERK in GNAQ/GNA11-mutant cells resolved the signaling hierarchy: mutant Gα11 activates PLCβ→DAG→PKC, which then drives MAPK, providing a rationale for PKC-targeted therapy.\",\n      \"evidence\": \"PKC inhibitor (AEB071, AHT956) and MEK inhibitor treatment in mutant vs. wild-type cell lines and xenograft models\",\n      \"pmids\": [\"24141786\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the PKC-to-Ras intermediary not yet known\", \"Contribution of IP3/calcium branch to proliferation uncharacterized\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of Egr-1 as a transcriptional activator of the GNA11 promoter revealed a transcriptional regulatory input that could modulate Gα11 expression levels.\",\n      \"evidence\": \"Promoter-luciferase reporter, EMSA, Egr-1 overexpression with qPCR readout\",\n      \"pmids\": [\"23802749\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological relevance of Egr-1-driven GNA11 upregulation in vivo not tested\", \"No data on whether this regulation is tissue-specific\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Functional characterization of a germline gain-of-function GNA11 mutation (R60L) causing autosomal dominant hypocalcemia demonstrated that Gα11 is the critical transducer coupling CaSR to intracellular calcium in parathyroid physiology.\",\n      \"evidence\": \"Whole-exome sequencing of affected family, mutant Gα11 expressed in HEK293-CaSR cells with quantitative calcium EC50 measurement\",\n      \"pmids\": [\"24823460\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of R60L gain-of-function not resolved\", \"Relative contribution of GNA11 vs. GNAQ to CaSR signaling in parathyroid not dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Characterization of the loss-of-function T54M mutation causing FHH2 revealed that the Gα11 helical/GTPase domain interface is critical for GDP binding and receptor-coupled signaling, explaining a distinct disease mechanism from gain-of-function alleles.\",\n      \"evidence\": \"3D homology modeling, functional expression in HEK293-CaSR cells with flow cytometry-based calcium measurement\",\n      \"pmids\": [\"26729423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of Gα11 itself; based on homology model\", \"Whether T54M affects GTP binding/hydrolysis kinetics not directly measured\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Structure-guided mutagenesis of the Gα11 hydrophobic cleft (including the disease-causing F220S mutation) established this surface as the PLCβ-activation interface, mechanistically linking loss-of-function GNA11 mutations to impaired PLC and MAPK signaling in FHH2.\",\n      \"evidence\": \"Homology modeling, site-directed mutagenesis of hydrophobic cleft residues, intracellular calcium and ERK assays in HEK293-CaSR cells, cinacalcet rescue in vitro and in vivo\",\n      \"pmids\": [\"28833550\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct structural data (co-crystal of Gα11–PLCβ) still lacking\", \"Whether other effectors also engage this cleft not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identification of RasGRP3 as the critical intermediate linking PKC/DAG downstream of mutant GNA11 to Ras activation closed the gap between Gα11→PLCβ and MAPK, defining the full oncogenic signaling cascade in uveal melanoma.\",\n      \"evidence\": \"GNA11(Q209L) transgenic mouse model, integrative transcriptomics, siRNA knockdown in human UVM lines, in vivo tumor assays\",\n      \"pmids\": [\"29490280\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RasGRP3 is activated by DAG directly or via PKC phosphorylation not fully resolved\", \"Applicability to non-UVM GNA11-mutant tumors not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showing that GNA11 knockdown selectively impairs FGF2/VEGFA-stimulated endothelial migration (but not proliferation) via PLCβ3 phosphorylation extended Gα11 function beyond GPCR-canonical signaling to growth factor receptor–coupled endothelial biology.\",\n      \"evidence\": \"siRNA knockdown in HUVECs, migration/proliferation/permeability assays, phospho-PLCβ3 immunoblotting\",\n      \"pmids\": [\"29659033\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which RTK signaling engages Gα11 is unclear\", \"Single siRNA-based study without genetic rescue\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Proteomic comparison revealed that GNAQ and GNA11, despite functional overlap in UVM, have distinct protein interaction partners—TET2 binds GNAQ but not GNA11—suggesting paralog-specific effector coupling.\",\n      \"evidence\": \"Tandem-affinity purification, mass spectrometry, immunoprecipitation\",\n      \"pmids\": [\"35580369\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of differential TET2 interaction not tested\", \"No reciprocal GNA11-specific interactors highlighted\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating that mosaic activating GNA11/GNAQ variants hyperactivate calcium signaling through calcium-release-activated channels, and that allele-specific siRNA or CRAC inhibition rescues this, established a calcium-centric pathomechanism for Sturge-Weber-like vascular anomalies and identified a druggable target.\",\n      \"evidence\": \"Two cellular models of mosaic variants, calcium imaging, allele-specific siRNA, CRAC channel inhibitor\",\n      \"pmids\": [\"37802293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo validation of CRAC inhibition in vascular malformation models not shown\", \"Relative contribution of IP3R vs. CRAC to pathology not fully resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Genome-scale CRISPR screens identified INPP5A as a synthetic lethal dependency in GNA11/GNAQ-mutant UVM, revealing that mutant cells depend on IP3 metabolism to prevent IP3R-mediated calcium overload and p53-dependent apoptosis—mechanistically separating the IP3/calcium toxicity arm from the pro-proliferative MAPK arm.\",\n      \"evidence\": \"Genome-scale CRISPR screen, IP3/IP4 measurements, calcium assays, Gq/11 inhibitor, in vivo xenograft validation\",\n      \"pmids\": [\"38233483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical translatability of INPP5A targeting not established\", \"Whether p53-independent death pathways also contribute is unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the direct structural basis of Gα11–PLCβ engagement (no Gα11 co-crystal exists), the mechanism by which Gα11 couples to RTK-driven migration, and whether paralog-specific interactors of GNA11 (distinct from GNAQ) mediate non-overlapping physiological functions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of Gα11 alone or in complex with PLCβ\", \"Mechanism of Gα11 engagement by growth factor receptor signaling unresolved\", \"Paralog-specific effectors of GNA11 versus GNAQ not functionally characterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [0, 3, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 5, 6, 10]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 5, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 5, 9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 5, 6, 9, 10]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 6, 10]}\n    ],\n    \"complexes\": [\n      \"heterotrimeric Gq protein (Gα11/β/γ)\"\n    ],\n    \"partners\": [\n      \"GNAQ\",\n      \"PLCB3\",\n      \"RASGRP3\",\n      \"INPP5A\",\n      \"CASR\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}